本文来自彭博终端，终端用户可运行NSN T06LY9GPFHVK 阅读原文。非终端用户可点击文末 "阅读原文" 预约演示。 全球市场版图日新月异，彭博行业研究（Bloomberg Intelligence）为您的企业战略助力。在 制药与生物技术领域，无论是全球行业资讯与热点，还是制药管线里程碑及催化剂事件、财务 预测…… BI涵盖广泛且深度的关键信息，旨在为您的决策提供可靠且具有竞争力的洞见支撑。 扫描二维码 立即订阅 彭博生物制药双周报 根据彭博行业研究的专有数据库，上半年授权交易数量（剔除联合试验）持续下滑，总计 2 4 1宗，为六年来最低水平。同期，大型药企签订了5 2宗交易，与过去两年的低迷水平持 平。交易放缓的主要原因是强生、葛兰素史克、默克与诺华的交易减少。强生将其重心转向 并购，而默克则仍相对不活跃。 上半年，礼来和阿斯利康分别以11宗和8宗交易领跑。礼来的交易范围涵盖中枢神经系统、 心血管代谢等疾病领域，其中1 0宗交易处于临床前阶段。阿斯利康则专注于癌症（4宗）和 免疫领域（4宗）。预付款金额最大（1 6 . 5亿美元）的交易是罗氏与Ze a l a n d Ph a rma达成的 协议。 ...

Joining us now to discuss the new developments is Dr. . Angela Fitch. She is a primary care clinician and the past president of the Obesity Medicine Association.Dr. . Fitch, welcome. >> Thank you for having me.>> So, we've been seeing GLP1s everywhere, Dr. . Fitch, but injectables. Now, we have the potential of this pill hitting the market with this drug trial with Eli Liy.What is it and how is it affecting folks. >> So, the other GLP ones we have, they're very hard to get into the system orally. That's why ...

摩根大通发表报告指，礼来在第二季财报公布后，是该行在美国大型生技制药股中首选标的。分析师写 道，虽然orforglipron在肥胖症减重的第三期试验数据略低于预期，仍认为该产品在市场中有明确定位， 同时礼来的核心可注射incretin药物系列依然处于最佳竞争位置。他们补充称，在上周股价回档之后， 礼来目前本益比仅约为2025年每股盈余预估值的29倍，以及2026年每股盈余预估值的21倍，且这些为保 守预估值。 ...

Market Overview - Major U.S. stock indices experienced a collective decline, with the Dow Jones Industrial Average falling by 200.52 points (0.45%) to close at 43,975.09 points, the Nasdaq down by 64.62 points (0.30%) at 21,385.40 points, and the S&P 500 decreasing by 16.00 points (0.25%) to 6,373.45 points [1] - Large-cap tech stocks mostly declined, with Apple down 0.83%, Amazon down 0.62%, Facebook down 0.45%, Nvidia down 0.3%, Google down 0.21%, and Microsoft down 0.02% [3][4] Notable Stock Movements - Tesla saw an increase of nearly 3%, marking its fourth consecutive day of gains [3] - Fannie Mae rose over 15% and Freddie Mac increased by more than 13%, both reaching their highest closing levels since 2008 [3] Sector Performance - Bank stocks showed mixed results, with Morgan Stanley up 0.53%, Bank of America up 0.38%, and JPMorgan up 0.32%. Conversely, Citigroup fell by 0.44%, Goldman Sachs down 0.24%, and Wells Fargo down 0.31% [5] - Gold stocks generally declined, with Harmony Gold, Eldorado Gold, and AngloGold down over 1%, and Coeur Mining down 0.3% [5] Chinese Stocks - The Nasdaq Golden Dragon China Index fell by 0.29%, with individual stocks showing mixed performance. Xpeng Motors rose nearly 6%, Tencent Music up over 2%, while NIO, Bilibili, and Xiaoma Zhixing increased by over 1%. On the downside, WeRide fell over 4%, TAL Education down more than 3%, and Li Auto down nearly 3% [6] Commodity Prices - The FTSE A50 futures index fell by 0.32% to 13,881 points [9] - Crude oil prices saw slight increases, with WTI crude up by 8 cents to $63.96 per barrel (0.13% increase) and Brent crude up by 4 cents to $66.63 per barrel (0.06% increase) [9] - Gold futures dropped by 2.78% to $3,394.1 per ounce, while silver futures fell by 2.29% to $37.66 per ounce [10] Currency Exchange - The offshore RMB (CNH) against the USD was reported at 7.1965, a decrease of 72 points from the previous Friday's close [11] Economic Indicators - Attention is focused on upcoming U.S. inflation data, particularly the Consumer Price Index (CPI) for July, which is expected to provide insights into the impact of tariffs on consumer prices [12][13]

周一，美国科技股七巨头指数跌0.25%，报188.78点。苹果收跌0.83%，亚马逊跌0.62%，Meta Platforms、英伟达、谷歌A、微软至多跌0.35%，特斯拉涨2.85%——该公司申请向英国家庭供电。此 外，AMD收跌0.28%，伯克希尔哈撒韦B类股跌0.14%，台积电ADR则收涨0.11%，礼来制药涨1.53%。 本文源自：金融界AI电报 ...

Core Insights - The global pharmaceutical sales ranking for the first half of 2025 has been released, highlighting the dominance of GLP-1 drugs in the market, with the top three drugs surpassing $10 billion in sales, driving industry growth [2][5] - The competition among pharmaceutical giants is intensifying, particularly in the GLP-1 category, with Novo Nordisk and Eli Lilly leading the charge [5][6] Group 1: GLP-1 Drug Market - GLP-1 drugs are the main drivers of market growth, contributing nearly 30% to the global biopharmaceutical market [3][5] - Semaglutide from Novo Nordisk topped the sales chart with $16.632 billion, while Eli Lilly's tirzepatide followed closely with $14.734 billion, marking a significant year-on-year growth of 121.3% [5][6] - The competitive landscape is shifting, with semaglutide's various formulations (injection, oral, and weight loss) ending Keytruda's long-standing dominance [5][6] Group 2: Emerging Therapies - New therapies such as bispecific antibodies, antibody-drug conjugates (ADC), and fusion proteins are gaining traction, accounting for over 15% of the top-selling drugs [3][10] - ADC drug Enhertu made its debut in the top rankings with $3.9 billion in sales, indicating a growing interest in innovative therapies [3][10] Group 3: CDK4/6 Inhibitors - The CDK4/6 inhibitor market is experiencing a reshuffle, with Eli Lilly's Abemaciclib leading at $2.648 billion, while Novartis' Ribociclib showed a remarkable growth rate of 58.7% [10] - Pfizer's Palbociclib, once a market leader, has seen a decline, dropping to $2.026 billion in sales [10] Group 4: BTK Inhibitors - The BTK inhibitor market is projected to reach approximately $12.5 billion by 2024, with Ibrutinib, Zebrutinib, and Acalabrutinib dominating the market [11][12] - Zebrutinib from BeiGene has entered the global top 50 list with $1.742 billion in sales, marking a significant achievement for Chinese innovation in the pharmaceutical sector [12][13]

智通财经APP获悉，周一，礼来(LLY.US)股价走高，截至发稿，该股涨3.8%，报649.66美元。消息面 上，德意志银行分析师James Shin维持礼来"买入"评级，但下调目标价至900美元。富瑞集团分析师 Akash Tewari、摩根士丹利分析师Terence Flynn、摩根大通分析师Chris Schott、花旗分析师Geoff Meacham、Truist Financial分析师Srikripa Devarakonda同样维持该股"买入"评级。 ...

Core Insights - The global pharmaceutical sales ranking for the first half of 2025 has been released, highlighting the dominance of GLP-1 drugs in the market, with the top three drugs surpassing $10 billion in sales, driving industry growth [1][6][13] - The competition among global pharmaceutical giants is intensifying, particularly in the metabolic drug sector, with companies like Novo Nordisk and Eli Lilly expected to expand their advantages [2][4] Group 1: GLP-1 Drug Market - GLP-1 drugs are leading the market, with Novo Nordisk's semaglutide family generating $16.632 billion in sales, marking its first position in the ranking [6] - Eli Lilly's tirzepatide follows closely with $14.734 billion in sales, showing a remarkable year-on-year growth of 121.3% [6] - The sales dynamics indicate that semaglutide's injection version holds a 61% market share, while the oral version accounts for 29% [6][7] Group 2: Emerging Therapies - New therapies such as bispecific antibodies, antibody-drug conjugates (ADC), and fusion proteins are gaining traction, accounting for over 15% of the market [1][13] - ADC drug Enhertu has entered the top rankings with $3.9 billion in sales [1] - mRNA vaccines have collectively contributed $9.4 billion, showcasing the impact of innovative therapies in the pharmaceutical landscape [1] Group 3: CDK4/6 Inhibitors - The CDK4/6 inhibitor market is experiencing a reshuffle, with Eli Lilly's Abemaciclib leading at $2.648 billion, while Novartis's Ribociclib has surged with a 58.7% growth [10][11] - Pfizer's Palbociclib has seen a decline, dropping to $2.026 billion, marking a significant shift in market dynamics [11] Group 4: Chinese Pharmaceutical Innovations - The entry of Chinese innovation, specifically BeiGene's Zebrutinib, into the global top 50 with $1.742 billion in sales signifies a breakthrough for domestic drugs [12] - Zebrutinib's success reflects the potential for Chinese pharmaceuticals to transition from thematic investments to performance-driven investments in the global market [12]

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **Biopharma** industry in **North America** with a comprehensive analysis of the **US drug market** as per **IQVIA Rx** data [1][6]. Core Insights - The **Total Prescription Year-over-Year (YoY) growth** for the week ending August 1, 2025, was reported at **+2.8%**, an increase from **+1.7%** the previous week and **+2.6%** over the past 12 weeks [1][6]. - For the week ended August 1, the **US total market weekly TRx YoY change** was **+2.8%**, compared to **+0.9%** a year ago. The **rolling 4-week TRx YoY** was **+2.9%** and the **rolling 12-week TRx YoY** was **+2.6%** [2]. Company-Specific Developments - **Bristol Myers Squibb (BMY)**: - The drug **Cobenfy** was approved for schizophrenia on September 26, 2024. The current scripts are approximately **2,010** for the week, up from **1,950** the previous week. To meet 2025 consensus expectations, Cobenfy's TRx needs to track at **~2-3x** the volumes from recent schizophrenia launches [3]. - The consensus estimate for Cobenfy has decreased from **$196 million** to **$171 million**, implying that approximately **129K TRx** are required to meet these estimates [3]. - **Vertex Pharmaceuticals (VRTX)**: - The drug **Journavx** was approved for acute pain on January 30, 2025, with current scripts at approximately **6,800**, up from **6,430** the previous week. It is noted that hospital scripts, which account for about **35%** of total scripts, are not captured by IQVIA [4]. - To achieve a sales target of **$78 million**, approximately **345K total scripts** are needed, assuming a **$225 net price per script** [4]. - **Gilead Sciences (GILD)**: - The launch comparison for **Yeztugo** (lenacapavir) shows current TRx at approximately **210**, down from **300** the previous week. The injectable formulation accounts for **50%** of total TRx [5]. Additional Insights - The **extended unit (EUTRx)** weekly YoY growth was reported at **+1.9%**, which is below the TRx YoY growth [2]. - The **sequential weekly TRx growth** was **-0.1%**, an improvement from **-1.2%** the week before [2]. - The **biopharma industry view** is categorized as **attractive**, while the major pharmaceuticals industry view is **in-line** [7]. Notable Trends - The **momentum of top outpatient drugs** indicates varying performance across different companies, with notable declines in some established drugs like **Humira** (AbbVie) showing a **-40%** YoY change, while newer drugs like **Mounjaro** (Eli Lilly) and **Zepbound** (Eli Lilly) show significant growth rates of **69%** and **257%** respectively [24]. Conclusion - The conference call highlights a positive trend in the US drug market with specific growth in total prescriptions. However, individual company performance varies significantly, with newer drugs showing strong growth potential while established drugs face declines. The insights provided can guide investment decisions in the biopharma sector.

Summary of Conference Call Records Industry Overview - The innovative drug sector is experiencing a short-term correction, but it is not affected by Trump's tariffs, providing a buying opportunity [1] - The GLP-1 market is thriving, with Novo Nordisk and Eli Lilly's weight loss drug sales exceeding $30 billion in the first half of the year, expected to reach $60-65 billion for the full year [1][4] - The global innovative drug market is projected to reach $1.5 trillion by 2030, with China expected to account for 30%, corresponding to a market value of approximately $6 trillion, indicating significant growth potential from the current $2.6 trillion [1][5] Key Companies and Performance - Novo Nordisk's semaglutide sales reached $5.458 billion in the first half of the year, a 78% year-on-year increase, but the company lowered its full-year guidance due to market competition and the impact of Eli Lilly's tirzepatide [1][9] - Eli Lilly's tirzepatide sales reached $5.69 billion in the first half, a 223% year-on-year increase, and the company raised its full-year revenue guidance [1][9] - The oral GLP-1 drug development trend is shifting towards multi-target iterations, but development remains challenging [3][10] Market Dynamics - The A-share pharmaceutical index fell by 0.8% this week but has risen by 21.2% since the beginning of the year, outperforming the CSI 300 by 26.9% [2] - The performance of various sectors within the pharmaceutical industry shows mixed results, with medical devices up by 3% and traditional Chinese medicine down by 1.9% [2] Investment Opportunities - The innovative drug export logic is shifting from domestic to overseas markets, with leading companies like BeiGene expected to see significant revenue growth, projected to reach $5 billion by 2025 [5] - The market share of Chinese innovative drugs in the global market is expected to increase from 5% to 30% through business development (BD) strategies [5] - Recommended companies with high growth potential include Innovent, 3SBio, and BeiGene, with a focus on companies like Boryung Pharmaceutical, which could reach a market value of $200 billion if successful in overseas expansion [8][11] Additional Insights - The current market share of A-shares and H-shares in the innovative sector is low at 1.7% and 1.8%, respectively, compared to 3.5% in the US market, indicating substantial growth potential [6] - The oral GLP-1 drug delivery methods are evolving, with Boryung's technology achieving over 8% bioavailability, positioning it as a leader in the industry [10]